98 related articles for article (PubMed ID: 25477088)
1. TKIs may be option for Ph-like ALL.
Cancer Discov; 2014 Dec; 4(12):1359-60. PubMed ID: 25477088
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.
Tanasi I; Ba I; Sirvent N; Braun T; Cuccuini W; Ballerini P; Duployez N; Tanguy-Schmidt A; Tamburini J; Maury S; Doré E; Himberlin C; Duclos C; Chevallier P; Rousselot P; Bonifacio M; Cavé H; Baruchel A; Dombret H; Soulier J; Landman-Parker J; Boissel N; Clappier E
Blood; 2019 Oct; 134(16):1351-1355. PubMed ID: 31434701
[No Abstract] [Full Text] [Related]
3. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
Hu T; Ciccarelli BT
Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
[No Abstract] [Full Text] [Related]
4.
Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
[TBL] [Abstract][Full Text] [Related]
5. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
6. [III.Acute Lymphoblastic Leukemia].
Imai K
Gan To Kagaku Ryoho; 2017 May; 44(5):392-396. PubMed ID: 28536334
[No Abstract] [Full Text] [Related]
7. Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives.
Kotb A; El Fakih R; Hanbali A; Hawsawi Y; Alfraih F; Hashmi S; Aljurf M
Exp Hematol; 2018 Nov; 67():1-9. PubMed ID: 30075295
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
9. Reaping the benefits of recent advances for adults with acute lymphoblastic leukemia.
Brown PA; Alvarnas JC
J Natl Compr Canc Netw; 2012 Jul; 10(7):800-1. PubMed ID: 22773795
[No Abstract] [Full Text] [Related]
10. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
Roberts KG; Janke LJ; Zhao Y; Seth A; Ma J; Finkelstein D; Smith S; Ebata K; Tuch BB; Hunger SP; Mullighan CG
Blood; 2018 Aug; 132(8):861-865. PubMed ID: 29880614
[No Abstract] [Full Text] [Related]
11. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
[No Abstract] [Full Text] [Related]
15. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Haematologica; 2017 Apr; 102(4):e160-e162. PubMed ID: 28057740
[No Abstract] [Full Text] [Related]
16. Targeted therapy for fusion-driven high-risk acute leukemia.
Pikman Y; Stegmaier K
Blood; 2018 Sep; 132(12):1241-1247. PubMed ID: 30049809
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
[TBL] [Abstract][Full Text] [Related]
18. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
19. Novel drug targets in acute leukemia.
Stock W
Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809
[No Abstract] [Full Text] [Related]
20. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
